Mycophenolate Mofetil-d4 (hydrochloride)

• UNSPSC Description:

  Mycophenolate Mofetil-d4 hydrochloride is deuterated labeled Mycophenolate mofetil hydrochloride (HY-B0199A). Mycophenolate mofetil (RS 61443) hydrochloride is a immunosuppressant, a non-competitive, selective and reversible inhibitor of inosine monophosphate dehydrogenase (IMPD) type I/II with IC50s of 39 nM and 27 nM, respectively.

• Target Antigen:

  Bacterial; Endogenous Metabolite; Isotope-Labeled Compounds

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Anti-infection;Metabolic Enzyme/Protease;Others

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Solubility:

  10 mM in DMSO

• Smiles:

  C/C(CCC(OC([2H])(C([2H])(N1CCOCC1)[2H])[2H])=O)=C\CC(C(O)=C2C(OCC2=C3C)=O)=C3OC.Cl

• Molecular Weight:

  473.98

• References & Citations:

  [1]Nakanishi, T., et al., Effect of the inosine 5'-monophosphate dehydrogenase inhibitor BMS-566419 on rat cardiac allograft rejection. Int Immunopharmacol, 2010. 10(1): p. 91-7.|[2]Dehghani, F., et al., Inhibition of microglial and astrocytic inflammatory responses by the immunosuppressant mycophenolate mofetil. Neuropathol Appl Neurobiol, 2010. 36(7): p. 598-611.|[3]Ozgen, M., et al., Mycophenolate mofetil and daclizumab targeting T lymphocytes in bleomycin-induced experimental scleroderma. Clin Exp Dermatol, 2012. 37(1): p. 48-54.|[4]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported